Evaluation of antitubercular drug‐loaded surfactants as inhalable drug‐delivery systems for pulmonary tuberculosis
Abstract
Pulmonary tuberculosis is associated with a year‐long chemotherapy, poor alveolar drug levels, drug‐related systemic toxicity, and patient noncompliance. In this study, exogenous pulmonary surfactant is proposed as a drug carrier for antitubercular drugs. Dipalmitoylphosphatidylcholine (DPPC), the major lung‐surfactant lipid, has been combined with antitubercular drugs isoniazid (INH), rifampicin (RFM), and ethambutol (ETH) in 1:1 ratio by weight, in which drugs had a ratio of 1:2:3 by weight. At 37°C, the formulation had better surfactant function with quicker reduction of surface tension on adsorption (32.71 ± 0.65 mN/m) than DPPC liposomes (44.67 ± 0.57 mN/m) and maintained 100% airway patency in a capillary surfactometer. Drug‐loaded surfactant liposomes were about 2 μm and had entrapment efficiency of 30.04% ± 2.05%, 18.85% ± 2.92%, and 61.47% ± 3.32% for INH, RFM, and ETH, respectively. Sustained release of the drugs from surfactants was observed over 24 h. In vitro alveolar deposition efficiency using the twin impinger showed 12.06% ± 1.87% of INH, 43.30% ± 0.87% of RFM, and 22.07% ± 2.02% of ETH deposited in the alveolar chamber upon nebulization for a minute using a jet nebulizer. The formulation was biocompatible and stable with physicochemical properties being retained even after storage for a month at 4°C. Antitubercular drug‐loaded surfactants developed could serve dual purposes of alveolar stabilization due to surfactant action and better reach of these drugs to the alveoli due to antiatelectatic effect of the surfactant. © 2008 Wiley Periodicals, Inc. J Biomed Mater Res, 2009
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
DPPC has been employed for INH delivery, but the loading efficiency was lower (~37%).
“DPPC has also been employed for INH delivery; however, the loading efficiency was found to be lower (~37%).209”
From Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles (2019) · cites this paper as [209]
The DPPC/INH formulation was biocompatible, and sustained release was maintained for up to 24 h with a burst release of 50% in the first 5 h.
“However, the formulation was biocompatible, and sustained release was maintained for up to 24 h with a burst release of 50% in the first 5 h.209”
From Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles (2019) · cites this paper as [209]
Cites
Aerosolized Ribavirin Treatment of Infants with Respiratory Syncytial Viral Infection
Hall, C. B., McBride, J. T., Walsh, E. E., Bell, D. M., Gala, C. L., Hildreth, S. W., Eyck, L. G. T., & Hall, W. J. (1983) · New England Journal of Medicine · doi:10.1056/nejm198306163082403 · Cited by 546 · see citing works
Surface active materials from dog lung. II. Composition and physiological correlations
King, R., & Clements, J. A. (1972) · American Journal of Physiology-Legacy Content · doi:10.1152/ajplegacy.1972.223.3.715 · Cited by 522 · see citing works
Hugli, T. E., & Müller‐Eberhard, H. J. (1978) · Advances in immunology · doi:10.1016/s0065-2776(08)60228-x · Cited by 502 · see citing works
Pandey, R. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg477 · Cited by 389 · see citing works
Deposition of aerosol in the respiratory tract.
Brain, J. D., & Valberg, P. A. (1979) · PubMed · doi:10.1164/arrd.1979.120.6.1325 · Cited by 384 · see citing works
Pandey, R., & Khuller, G. K. (2005) · Tuberculosis · doi:10.1016/j.tube.2004.11.003 · Cited by 318 · see citing works
Optimization of the sulforhodamine B colorimetric assay
Papazisis, K. T., Geromichalos, G. D., Dimitriadis, K. A., & Kortsaris, A. H. (1997) · Journal of Immunological Methods · doi:10.1016/s0022-1759(97)00137-3 · Cited by 311 · see citing works
Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages
Vyas, S. P., Kannan, M., Jain, S., Mishra, V. K., & Singh, P. (2003) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2003.08.017 · Cited by 262 · see citing works
Sharma, A., Sharma, S., & Khuller, G. K. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh411 · Cited by 251 · see citing works
Surfactant-associated proteins: functions and structural variation
Haagsman, H. P., & Diemel, R. V. (2001) · Comparative Biochemistry and Physiology Part A Molecular & Integrative Physiology · doi:10.1016/s1095-6433(01)00308-7 · Cited by 209 · see citing works
Sharma, R., Saxena, D., Dwivedi, A. K., & Misra, A. (2001) · Pharmaceutical Research · doi:10.1023/a:1012296604685 · Cited by 201 · see citing works
In vitro hemolysis of human erythrocytes — by plant extracts with antiplasmodial activity
Sharma, P., & Sharma, J. D. (2001) · Journal of Ethnopharmacology · doi:10.1016/s0378-8741(00)00370-6 · Cited by 183 · see citing works
Suarez, S., O’Hara, P. J., Kazantseva, M., Newcomer, C. E., Hopfer, R. L., McMurray, D. N., & Hickey, A. J. (2001) · Pharmaceutical Research · doi:10.1023/a:1013094112861 · Cited by 159 · see citing works
Vogelenzang, E. H. (1975) · Journal of the American Pharmaceutical Association (1961) · doi:10.1016/s0003-0465(16)33412-7 · Cited by 149 · see citing works
Pulmonary Surfactant Maintains Patency of Conducting Airways in the Rat
Enhörning, G., Duffy, L. C., & Welliver, C. (1995) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.151.2.7842219 · Cited by 120 · see citing works
Pulmonary delivery of liposomes
Schreier, H., Gonzalez‐Rothi, R. J., & Stecenko, A. A. (1993) · Journal of Controlled Release · doi:10.1016/0168-3659(93)90180-d · Cited by 118 · see citing works
Hallworth, G. W., & Westmoreland, D. G. (1987) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1987.tb03142.x · Cited by 117 · see citing works
Schaad, U. B., Wedgwood, J., Suter, S., & Kraemer, R. (1987) · The Journal of Pediatrics · doi:10.1016/s0022-3476(87)80130-0 · Cited by 99 · see citing works
Kharasch, V. S., Sweeney, T. D., Fredberg, J. J., Lehr, J. L., Damokosh, A. I., Avery, M. E., & Brain, J. D. (1991) · American Review of Respiratory Disease · doi:10.1164/ajrccm/144.4.909 · Cited by 97 · see citing works
Exogenous surfactant as a drug delivery agent
Haitsma, J. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00106-5 · Cited by 75 · see citing works
Inhibition of pulmonary surfactant by oleic acid: mechanisms and characteristics
Hall, S. B., Lu, R. Z., Venkitaraman, A. R., Hyde, R. W., & Notter, R. H. (1992) · Journal of Applied Physiology · doi:10.1152/jappl.1992.72.5.1708 · Cited by 72 · see citing works
Veen, A. V. '., Mouton, J. W., Gommers, D. A. M. P. J., & Lachmann, B. (1996) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1996.tb16016.x · Cited by 63 · see citing works
Enhörning, G. (2001) · Comparative Biochemistry and Physiology Part A Molecular & Integrative Physiology · doi:10.1016/s1095-6433(01)00318-x · Cited by 61 · see citing works
Agrawal, S., Singh, I., Kaur, K. J., Bhade, S. R., Kaul, C. L., & Panchagnula, R. (2004) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2004.02.019 · Cited by 61 · see citing works
Selecting and using nebuliser equipment
Kendrick, A. H., Smith, E. C., & Wilson, R. S. (1997) · Thorax · doi:10.1136/thx.52.2008.s92 · Cited by 60 · see citing works
Preparation and evaluation of a liposomal formulation of sodium cromoglicate
Nagarsenker, M. S., & Londhe, V. Y. (2003) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(02)00583-5 · Cited by 48 · see citing works
Veen, A. V. '., Mouton, J. W., Gommers, D. A. M. P. J., Kluytmans, J. A. J. W., Dekkers, P., & Lachmann, B. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.2.329 · Cited by 47 · see citing works
Tomoda, K., Kojima, S., Kajimoto, M., Watanabe, D., Nakajima, T., & Makino, K. (2005) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2005.06.014 · Cited by 46 · see citing works
Liposome-based antitubercular drug therapy in a guinea pig model of tuberculosis
Pandey, R., Sharma, S., & Khuller, G. K. (2004) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2004.01.002 · Cited by 39 · see citing works
Leonenko, Z., Finot, É., Vassiliev, V., & Amrein, M. (2006) · Ultramicroscopy · doi:10.1016/j.ultramic.2006.02.007 · Cited by 36 · see citing works
Why Pulmonary Tuberculosis Recurs: A Population-based Epidemiological Study
Selassie, A. W., Pozsik, C. J., Wilson, D. A., & Ferguson, P. L. (2005) · Annals of Epidemiology · doi:10.1016/j.annepidem.2005.03.002 · Cited by 34 · see citing works
Chimote, G., & Banerjee, R. (2005) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2005.08.014 · Cited by 32 · see citing works
Self-citationAgrawal, S. K., SINGH, I., KAUR, K., Bhade, S. R., Kaul, C. L., & Panchagnula, R. (2004) · Pharmacological Research · doi:10.1016/j.phrs.2004.01.009 · Cited by 30 · see citing works
Chimote, G., & Banerjee, R. (2004) · Respiratory Physiology & Neurobiology · doi:10.1016/j.resp.2004.10.003 · Cited by 27 · see citing works
Self-citationSaigal, S., Robertson, C. M. T., Sankaran, K., Bingham, W., CASIRO, O. G., MacMurray, B., Whitfield, M. G., & Long, W. A. (1995) · The Journal of Pediatrics · doi:10.1016/s0022-3476(95)70009-9 · Cited by 21 · see citing works
Effects of albumin and erythrocyte membranes on spread monolayers of lung surfactant lipids
Rachana, R., & Banerjee, R. (2006) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2006.03.017 · Cited by 17 · see citing works
Self-citationRachana, R., & Banerjee, R. (2004) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2003.12.001 · Cited by 15 · see citing works
Self-citationVeen, A., Wollmer, P., Nilsson, L.-E., Gommers, D., Mouton, J., Kooy, P., & Lachmann, B. (. (1998) · EUR Research Repository (Erasmus University Rotterdam) · Cited by 1 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles
Singh, A. P., Biswas, A., Shukla, A., & Maiti, P. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0068-3 · Cited by 645 · see citing works
Inhaled drug therapy for treatment of tuberculosis
Misra, A., Hickey, A. J., Rossi, C. R., Borchard, G., Terada, H., Makino, K., Fourie, P. B., & Colombo, P. (2010) · Tuberculosis · doi:10.1016/j.tube.2010.08.009 · Cited by 171 · see citing works
Therapeutic Liposomal Dry Powder Inhalation Aerosols for Targeted Lung Delivery
Willis, L., Hayes, D., & Mansour, H. M. (2012) · Lung · doi:10.1007/s00408-011-9360-x · Cited by 148 · see citing works
The formulation of nanomedicines for treating tuberculosis
Costa, A., Pinheiro, M., Magalhães, J., Ribeiro, R., Seabra, V., Reis, S., & Sarmento, B. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.012 · Cited by 123 · see citing works
Liposomes as Drug Delivery Systems for The Treatment of TB
Pinheiro, M., Lúcio, M., Lima, J. L. F. C., & Reis, S. (2011) · Nanomedicine · doi:10.2217/nnm.11.122 · Cited by 115 · see citing works
The function and performance of aqueous aerosol devices for inhalation therapy
Carvalho, T. C., & McConville, J. T. (2016) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12541 · Cited by 105 · see citing works
Present status of nanoparticle research for treatment of Tuberculosis
Shegokar, R., Shaal, L. A., & Mitri, K. (2011) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3m59p · Cited by 87 · see citing works
Inhaled drug treatment for tuberculosis: Past progress and future prospects
Hickey, A. J., Durham, P. G., Dharmadhikari, A., & Nardell, E. A. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.11.018 · Cited by 81 · see citing works
Anestopoulos, I., Kiousi, D. E., Klavaris, A., Galanis, Α., Sałek, K., Euston, S. R., Pappa, A., & Panayiotidis, M. I. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12070688 · Cited by 81 · see citing works
Henderson, M. C., Siddens, L. K., Morré, J. T., Krueger, S. K., & Williams, D. E. (2008) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2008.09.017 · Cited by 71 · see citing works
Mansour, H. M., Duan, Vogt, Li, & Hayes, D. (2013) · International Journal of Nanomedicine · doi:10.2147/ijn.s48631 · Cited by 59 · see citing works
Hussain, A., Singh, S., Das, S. S., AnjiReddy, K., Karpagam, S., & Shakeel, F. (2019) · Current Drug Delivery · doi:10.2174/1567201816666190201144815 · Cited by 52 · see citing works
Joshi, N., Shirsath, N., Singh, A. K., Joshi, K., & Banerjee, R. (2014) · Scientific Reports · doi:10.1038/srep07085 · Cited by 49 · see citing works
Self-citationViswanathan, V., Pharande, R. R., Bannalikar, A. S., Gupta, P., Gupta, U. D., & Mukne, A. (2018) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2018.1513025 · Cited by 43 · see citing works
Jadhav, A., & Nagaraj, K. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17060779 · Cited by 35 · see citing works
A review of formulations and preclinical studies of inhaled rifampicin for its clinical translation
Khadka, P., Dummer, J. F., Hill, P. C., Katare, R., & Das, S. C. (2022) · Drug Delivery and Translational Research · doi:10.1007/s13346-022-01238-y · Cited by 32 · see citing works
Advancement in pulmonary drug delivery systems for treatment of tuberculosis
Goyal, A. K., Garg, T., Bhandari, S., & Rath, G. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-46143-6.00022-1 · Cited by 25 · see citing works
Proapoptotic lipid nanovesicles: Synergism with paclitaxel in human lung adenocarcinoma A549 cells
Joshi, N., Shanmugam, T., Kaviratna, A., & Banerjee, R. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.07.025 · Cited by 24 · see citing works
Self-citationLiposomes for Pulmonary Drug Delivery
Swaminathan, J., & Ehrhardt, C. (2011) · Springer eBooks · doi:10.1007/978-1-4419-9745-6_14 · Cited by 24 · see citing works
Sankhe, K., Khan, T., Bhavsar, C., Momin, M., & Omri, A. (2019) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2019.1609937 · Cited by 18 · see citing works
Shanmugam, T., Joshi, N., Kaviratna, A., Ahamad, N., Bhatia, E., & Banerjee, R. (2020) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.0c01126 · Cited by 16 · see citing works
Self-citationTai, W., Arnold, J. C., Chan, H., & Kwok, P. C. L. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124235 · Cited by 15 · see citing works
In vitro controlled release of tuberculosis drugs by amphiphilic branched copolymer nanoparticles
Gajendiran, M., Jo, H., Kim, K., & Balasubramanian, S. (2019) · Journal of Industrial and Engineering Chemistry · doi:10.1016/j.jiec.2019.04.033 · Cited by 15 · see citing works
Joshi, N., Kaviratna, A., & Banerjee, R. (2012) · Integrative Biology · doi:10.1039/c2ib20122d · Cited by 15 · see citing works
Self-citationZhu, J., Dang, H.-C., Wang, W.-T., Wang, X., & Wang, Y. (2011) · Journal of Biomaterials Science Polymer Edition · doi:10.1163/092050610x497863 · Cited by 12 · see citing works
Nanosized devices as antibiotics and antifungals delivery: past, news, and outlook
Furneri, P. M., Petronio, G. P., Fuochi, V., Cupri, S., & Pignatello, R. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-46143-6.00023-3 · Cited by 12 · see citing works
Liposome-Encapsulated Antibiotics for the Therapy of Mycobacterial Infections
Yıldırım, M., & Düzgüneş, N. (2025) · Antibiotics · doi:10.3390/antibiotics14070728 · Cited by 10 · see citing works
NANOPARTICLES AS DRUG DELIVERY SYSTEM FOR ANTITUBERCULOUS DRUGS
Sanzhakov, M. A., Ipatova, O. M., Torkhovskaya, T. I., Prozorovskii, V. N., Tikhonova, E. G., Druzhilovskaya, O. S., & Medvedeva, N. V. (2013) · Annals of the Russian academy of medical sciences · doi:10.15690/vramn.v68i8.722 · Cited by 9 · see citing works
Excipients Utilized for Modifying Pulmonary Drug Release
Sheth, P., & Myrdal, P. B. (2011) · Springer eBooks · doi:10.1007/978-1-4419-9745-6_11 · Cited by 8 · see citing works
Nanotechnology as a potential tool against drug- and multidrug-resistant tuberculosis
Pérez-Martínez, D. E., & Zenteno‐Cuevas, R. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819811-7.00003-5 · Cited by 8 · see citing works
Nanostructures for Antimicrobial Therapy—The Modern Trends in the Treatment of Bacterial Infections
Maharramov, A. M., Рамазанов, М. А., & Hasanova, U. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-52733-0.00016-1 · Cited by 8 · see citing works
Gajendiran, M., Balashanmugam, P., Kalaichelvan, P. T., & Balasubramanian, S. (2016) · Materials Research Express · doi:10.1088/2053-1591/3/6/065401 · Cited by 6 · see citing works
Challenges and Opportunities of Nanotechnological based Approach for the Treatment of Tuberculosis
Rath, G., Pradhan, D., Ghosh, G., & Goyal, A. K. (2021) · Current Pharmaceutical Design · doi:10.2174/1381612827666210226121359 · Cited by 6 · see citing works
Controlled Transport for Pulmonary Drug Delivery
Fiegel, J., Brenza, T. M., & Hamed, R. (2011) · Springer eBooks · doi:10.1007/978-1-4419-9745-6_7 · Cited by 6 · see citing works
Nanomedicines in Tuberculosis: Diagnosis, Therapy and Nanodrug Delivery
Dakkah, A. N., Bataineh, Y. A., Al-Jaidi, B. A., Bayan, M. F., & Nimer, N. A. (2020) · Engineering materials · doi:10.1007/978-3-030-36260-7_13 · Cited by 3 · see citing works
A Comprehensive Study of Multi-Drug Resistance in Tuberculosis
Sharma, M., & Kansal, S. (2022) · Advances in medical education, research, and ethics (AMERE) book series · doi:10.4018/978-1-7998-8490-3.ch016 · Cited by 3 · see citing works
Pandya, S. M., Gupta, A., Ranjan, R., Sachan, M., Agrawal, A. K., & Misra, A. (2016) · Wiley eBooks · doi:10.1002/9781118943182.ch11 · Cited by 1 · see citing works
Intracellular Bacteria and Protozoa
Morilla, M. J., & Romero, E. L. (2011) · Fundamental biomedical technologies · doi:10.1007/978-94-007-1248-5_24
van Rensburg, L. (2012) · SUNScholar (Stellenbosch University)
Redkin, R. G., Орловецька, Н. Ф., & Dankevych, O. S. (2022) · News of pharmacy · doi:10.24959/nphj.22.91
- Authors
- Chimote, G., & Banerjee, R.
- Affiliations
- Indian Institute of Technology Bombay (IN)
- Corresponding author
- Banerjee, R.
- ORCID
- Banerjee, R.
- Venue
- Journal of Biomedical Materials Research Part A
- Publisher
- Wiley
- Published
- 2008-04-22
- Volume
- 89A
- Issue
- 2
- Pages
- 281-292
- ISSN
- 1549-3296 (ISSN-L)
- 1552-4965
- OpenAlex
- W2069778654
- Cited by
- 41
- References
- 38
- Citations by year
- 2025: 2 · 2024: 1 · 2022: 3 · 2021: 1 · 2020: 4 · 2019: 4 · 2018: 2 · 2017: 3 · 2016: 4 · 2015: 1 · 2014: 1 · 2013: 2 · 2012: 3
- FWCI
- 3.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Biomedical Materials Research Part A (publishedVersion)
- PubMed (publishedVersion)
- DSpace (IIT Bombay) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Inhalation and Respiratory Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- pulmonary tuberculosis, antitubercular agents, DPPC, isoniazid, rifampicin, ethambutol, pulmonary drug delivery, pulmonary surfactant, nebulization, sustained drug release, encapsulation efficiency
- MeSH terms
- Administration, Inhalation, Adsorption, Animals, Antitubercular Agents, Biocompatible Materials, Capillaries, Drug Stability, Humans, Liposomes, Particle Size, Surface-Active Agents, Tuberculosis, Pulmonary, Drug Delivery Systems, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
